PharmaMar’s Lurbinectedin to Be Marketed as Zepsyre After Approval as Ovarian Cancer Therapy

PharmaMar’s Lurbinectedin to Be Marketed as Zepsyre After Approval as Ovarian Cancer Therapy
Once approved, PharmaMar’s lurbinectedin (PM1183) will be marketed under the brand name Zepsyre as a treatment for solid tumors in ovarian, lung, and breast cancers. Zepsyre is in its final stage of development as an anticancer treatment. Selecting a brand name is part of the approval process by the European Medicines Agency and the U.S. Food and Drug Administration before a drug reaches market. “We trust in the potential of Zepsyre as a therapeutic alternative due to its novel mechanism of action and the antitumoral activity observed in all clinical trials for different type of tumors,” Luis Mora, managing director of PharmaMar’s Oncology Business Unit, said in a news release. Zepsyre works by inhibiting RNA polymerase II, an enzyme essential for protein production, causing cancer cell death and halting tumor growth. In a Phase 2 clinical trial for ovarian cancer patients who did not respond to platinum-based chemotherapy, treatment with Zepsyre induced an overall response rate of 22% and a disease control rate of 71%. Researchers also found that Zepsyre reverses IRF-1-dependent resistance to Platinol (cisplatin) in ovarian cancer tumors. Zepsyre’s efficacy and safety also are being studied in two Phase 3 trials — one in platinum-resistant ovarian cancer (NCT02421588) and another in platinum-resistant small-cell lung cancers (ATLANTIS, 
Subscribe or to access all post and page content.